Lung Cancer and Interstitial Lung Diseases: A Systematic Review

Table 1

Summary of the studies on incidence of lung cancer in interstitial lung diseases.

Study	Patients	Incidence of lung cancer
	IPF
Nagai et al. [23]	99	31 (31.3%)
Park et al. [24]	281	63 (22.4%)
Le Jeune et al. [26]	1064	29 (2.7%)
	Sarcoidosis
Le Jeune et al. [26]	1153	4 (0.3%)
Seersholm et al. [34]	254	5 (1.9%)
Boffetta et al. [35]	5768	37 (0.6%)
Romer et al. [36]	555	1 (0.2%)
	Scleroderma
Kang et al. [47]	112	4 (3.5%)
Hill et al. [48]	441	12 (2.7%)
Chatterjee et al. [49]	538	10 (1.8%)
Abu-Shakra et al. [55]	248	7 (2.8%)
Kyndt et al. [57]	123	3 (2.4%)
	DM/PM
Huang et al. [61]	1720	30 (1.7%)
Zhang et al. [62]	115	20 (17.4%) DM
Hill et al. [63]	1532	39 (2.5%)
	RA
Yamada et al. [67]	7566	34 (0.4%)
Parikh-Patel et al. [68]	84475	762 (0.9%)
Khurana et al. [69]	9015	247 (2.7%)
Takayanagi et al. [70]	86	14 (16.2%)
Abásolo et al. [72]	789	6 (0.7%)
	SLE
Bin et al. [77]	9500	30 (0.3%)
Bernatsky et al. [78]	9547	62 (0.6%)
Ramsey-Goldman et al. [81]	616	4 (0.6%)

Abbreviations: DM: dermatomyositis, IPF: idiopathic pulmonary fibrosis, PM: polymyositis, RA: rheumatoid arthritis, SLE: systemic lupus erythematosus.